MannKind | MNKD - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Adma Biologics USD 57.13M 4.47M 2026-03
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Eli Lilly USD 8.85B 583.8M 2026-03
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Insmed USD -11.37M 150.72M 2026-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
MacroGenics USD -36.77M 21.84M 2026-03
MannKind USD -16.37M 4.56M 2026-03
Merck USD -3.53B 6.95B 2026-03
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Novavax USD 17.9M 220.94M 2025-12
Novo Nordisk DKK 62.17B 36.66B 2026-03
Pfizer USD -653M 5.84B 2026-06
Sanofi EUR 837M 1.17B 2026-06
Xencor USD -21.92M 106.72M 2026-06